Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

This report describes the synthesis of two cyclic RGD (Arg-Gly-Asp) conjugates, HYNIC-2PEG(4)-dimer (HYNIC = 6-hydrazinonicotinyl; 2PEG(4)-dimer = E[PEG(4)-c(RGDfK)](2); and PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) and HYNIC-3PEG(4)-dimer (3PEG(4)-dimer = PEG(4)-E[PEG(4)-c(RGDfK)](2)), and evaluation of their (99m)Tc complexes [(99m)Tc(HYNIC-2PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-2PEG(4)-dimer: TPPTS = trisodium triphenylphosphine-3,3',3''-trisulfonate) and [(99m)Tc(HYNIC-3PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-3PEG(4)-dimer) as novel radiotracers for imaging integrin alpha(v)beta(3) expression in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts. The integrin alpha(v)beta(3) binding affinities of RGD peptides were determined by competitive displacement of (125)I-c(RGDyK) on U87MG glioma cells. It was found that the two PEG(4) linkers between RGD motifs in HYNIC-2PEG(4)-dimer (IC(50) = 2.8 +/- 0.5 nM) and HYNIC-3PEG(4)-dimer (IC(50) = 2.4 +/- 0.7 nM) are responsible for their higher integrin alpha(v)beta(3) binding affinity than that of HYNIC-PEG(4)-dimer (PEG(4)-dimer = PEG(4)-E[c(RGDfK)](2); IC(50) = 7.5 +/- 2.3 nM). Addition of extra PEG(4) linker in HYNIC-3PEG(4)-dimer has little impact on integrin alpha(v)beta(3) binding affinity. (99m)Tc-2PEG(4)-dimer and (99m)Tc-3PEG(4)-dimer were prepared in high yield with >95% radiochemical purity and the specific activity of >10 Ci/mumol. Biodistribution studies clearly demonstrated that PEG(4) linkers are particularly useful for improving the tumor uptake and clearance kinetics of (99m)Tc-2PEG(4)-dimer and (99m)Tc-3PEG(4)-dimer from noncancerous organs. It was also found that there was a linear relationship between the tumor size and radiotracer tumor uptake expressed as %ID (percentage of the injected dose) in U87MG glioma and MDA-MB-435 breast tumor models. The blocking experiment showed that the tumor uptake of (99m)Tc-2PEG(4)-dimer is integrin alpha(v)beta(3)-mediated. In the metabolism study, (99m)Tc-2PEG(4)-dimer had high metabolic stability during its excretion from renal and hepatobiliary routes. (99m)Tc-3PEG(4)-dimer also remained intact during thee excretion from the renal route, but, had approximately 30% metabolism during the excretion from the hepatobiliary route. Planar imaging studies in U87MG glioma and MDA-MB-435 breast tumor models showed that the tumors of approximately 5 mm in diameter could be readily visualized with excellent contrast. Thus, (99m)Tc-3PEG(4)-dimer is a very promising radiotracer for the early detection of integrin alpha(v)beta(3)-positive tumors, and may have the potential for noninvasive monitoring of tumor growth or treatment efficacy.

[1]  Multimodality Imaging of Tumor Angiogenesis: Perfusion Modeling for Tumor Angiogenesis , 2010 .

[2]  Weibo Cai,et al.  Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.

[3]  Matthias Glaser,et al.  Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.

[4]  Shuang Liu,et al.  99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. , 2008, Bioconjugate chemistry.

[5]  Fan Wang,et al.  Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. , 2008, Bioconjugate chemistry.

[6]  Shuang Liu,et al.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. , 2008, Nuclear medicine and biology.

[7]  W. Cai,et al.  microPET of Tumor Integrin αvβ3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) , 2007, Journal of Nuclear Medicine.

[8]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[9]  Arwin J. Brouwer,et al.  Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. , 2007, Organic & biomolecular chemistry.

[10]  W. Oyen,et al.  Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.

[11]  W. Oyen,et al.  Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Shuang Liu,et al.  Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.

[13]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[14]  H. Kessler,et al.  Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.

[15]  Shuang Liu.  Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .

[16]  Bing Jia,et al.  99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .

[17]  C. Pedone,et al.  Peptide‐based Molecules in Angiogenesis , 2006, Chemical biology & drug design.

[18]  Xiaoyuan Chen.  Multimodality imaging of tumor integrin alphavbeta3 expression. , 2006, Mini reviews in medicinal chemistry.

[19]  S. Gambhir,et al.  Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .

[20]  S. Mohammed,et al.  Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.

[21]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[22]  H. Ghandehari,et al.  Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[25]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[26]  R. Haubner,et al.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.

[27]  Horst Kessler,et al.  Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Jean-Luc Coll,et al.  Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. , 2004, Journal of the American Chemical Society.

[29]  Ryan Park,et al.  Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. , 2004, Molecular imaging.

[30]  M. Schwaiger,et al.  Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression , 2004, Nuklearmedizin.

[31]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[32]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.

[33]  J. Bading,et al.  Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.

[34]  Horst Kessler,et al.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.

[35]  K. Gottschalk,et al.  The Structures of Integrins and Integrin—Ligand Complexes: Implications for Drug Design and Signal Transduction. , 2003 .

[36]  S. Robinson,et al.  Integrin alphavbeta3 directed radiopharmaceuticals for tumor imaging , 2003 .

[37]  W. Oyen,et al.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. , 2002, Cancer biotherapy & radiopharmaceuticals.

[38]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[39]  Horst Kessler,et al.  The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. , 2002, Angewandte Chemie.

[40]  Manfred Schwab,et al.  Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. , 2002, Cancer research.

[41]  G. Slegers,et al.  Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  D. Edwards,et al.  Fundamentals of Receptor-Based Diagnostic Metalloradiopharmaceuticals , 2002 .

[43]  S. Libutti,et al.  Molecular imaging of tumor angiogenesis , 2002, Journal of cellular biochemistry. Supplement.

[44]  W. Oyen,et al.  Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .

[45]  S. Ray,et al.  Role of alphavbeta3 integrin receptors in breast tumor. , 2001, Journal of experimental & clinical cancer research : CR.

[46]  S. Denardo,et al.  Antiangiogenic agents and their promising potential in combined therapy. , 2001, Critical reviews in oncology/hematology.

[47]  M. Rajopadhye,et al.  (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. , 2001, Bioconjugate chemistry.

[48]  J. Barrett,et al.  99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. , 2001, Bioconjugate chemistry.

[49]  M Schwaiger,et al.  Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[50]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[51]  W. Diluzio,et al.  Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. , 2001, Journal of pharmaceutical sciences.

[52]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[54]  Shuang Liu,et al.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals , 1999 .

[55]  Vicki Brower,et al.  Tumor angiogenesis—new drugs on the block , 1999, Nature Biotechnology.

[56]  T. Harris,et al.  Synthesis of stable hydrazones of a hydrazinonicotinyl-modified peptide for the preparation of 99mTc-labeled radiopharmaceuticals. , 1999, Bioconjugate chemistry.

[57]  Horst Kessler,et al.  Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .

[58]  Shuang Liu,et al.  Technetium Complexes of a Hydrazinonicotinamide-Conjugated Cyclic Peptide and 2-Hydrazinopyridine: Synthesis and Characterization. , 1999, Inorganic chemistry.

[59]  V. V. van Hinsbergh,et al.  Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[61]  E Biganzoli,et al.  Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  A. Epenetos,et al.  Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide , 1998, European Journal of Nuclear Medicine.

[63]  A. Harris,et al.  A novel ternary ligand system for 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. , 1998, Bioconjugate chemistry.

[64]  S. Mousa.  MECHANISMS OF ANGIOGENESIS IN VASCULAR DISORDERS : POTENTIAL THERAPEUTIC TARGETS , 1998 .

[65]  J. Barrett,et al.  99mTc labeling of highly potent small peptides. , 1997, Bioconjugate chemistry.

[66]  Horst Kessler,et al.  Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy , 1997 .

[67]  A. Giannis,et al.  Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy , 1997 .

[68]  J. Barrett,et al.  New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. , 1997, Bioconjugate chemistry.

[69]  A. Rademaker,et al.  Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Malik,et al.  Arg-Gly-Asp peptide increases endothelial hydraulic conductivity: comparison with thrombin response. , 1995, The American journal of physiology.

[71]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[72]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[73]  S. Kennel,et al.  Expression of β1, β3, β4, and β5 Integrins by Human Lung Carcinoma Cells of Different Histotypes , 1994 .

[74]  S. Kennel,et al.  Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. , 1994, Experimental cell research.

[75]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.